MEDP
What one share of Medpace Holdings holds
Services – Commercial Physical and Biological Research
We are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries.
Medpace Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-09-30; the balance sheet is as of 2026-09-30.
| Sales | $98.84 |
|---|---|
| Profit | $18.03 |
| Capex (buildings and equipment) | $1.93 |
| Free cash flow | $23.25 |
| Cash and investments | $25.22 |
| Book value | $20.92 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $11.60 | $0.37 | $0.37 | $2.15 | — | $15.02 |
| 2017 | $10.95 | $0.98 | $0.29 | $2.15 | — | $14.36 |
| 2018 | $19.09 | $1.97 | $0.43 | $3.81 | — | $16.79 |
| 2019 | $22.91 | $2.67 | $0.48 | $4.90 | — | $20.14 |
| 2020 | $24.56 | $3.84 | $0.83 | $6.03 | — | $22.69 |
| 2021 | $30.30 | $4.81 | $0.75 | $6.24 | — | $26.47 |
| 2022 | $43.36 | $7.28 | $1.10 | $10.43 | — | $12.43 |
| 2023 | $59.23 | $8.88 | $1.15 | $12.46 | — | $18.18 |
| 2024 | $65.88 | $12.63 | $1.14 | $17.88 | — | $26.95 |
| 2025 | $85.69 | $15.28 | $1.06 | $23.09 | — | $16.18 |